Literature DB >> 31290366

Silk fibroin-based nanotherapeutics: application in the treatment of colonic diseases.

Shuangquan Gou1,2, Yamei Huang1,2,3, Junsik Sung4, Bo Xiao1,3,4, Didier Merlin4,5.   

Abstract

The incidence of colonic diseases (e.g., inflammatory bowel diseases and colon cancer) is rapidly rising. Nanotherapeutic has been considered as a promising strategy in the treatment of colonic diseases. Silk fibroin (SF) has been widely used as a drug-carrier matrix. Interestingly, SF-based nanoparticles (SFNPs) have intrinsic anti-inflammatory activity, wound healing capacity and lysosomal environment-responsive drug-release property. With further investigations, the sequences of SF molecules could be precisely modified through chemical reactions or transgenic techniques to greatly improve the properties of SFNPs. Here, we review recent advances in the application of SFNPs toward the treatment of colonic diseases. We also discuss future developments that might improve the anti-inflammatory and anti-colon cancer activities of SF-based nanotherapeutics.

Entities:  

Keywords:  colon cancer; inflammatory bowel disease; nanoparticle; silk fibroin; treatment

Year:  2019        PMID: 31290366      PMCID: PMC7026768          DOI: 10.2217/nnm-2019-0058

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  35 in total

1.  Tunable self-assembly of genetically engineered silk--elastin-like protein polymers.

Authors:  Xiao-Xia Xia; Qiaobing Xu; Xiao Hu; Guokui Qin; David L Kaplan
Journal:  Biomacromolecules       Date:  2011-09-30       Impact factor: 6.988

2.  Enhancement of anti-inflammatory activity of PEP-1-FK506 binding protein by silk fibroin peptide.

Authors:  Dae Won Kim; Hyun Sook Hwang; Duk-Soo Kim; Seung Hoon Sheen; Dong Hwa Heo; Gyojun Hwang; Suk Hyung Kang; Haeyong Kweon; You-Young Jo; Seok Woo Kang; Kwang-Gill Lee; Jinseu Park; Won Sik Eum; Yong-Jun Cho; Soo Young Choi
Journal:  J Microbiol Biotechnol       Date:  2012-04       Impact factor: 2.351

3.  Local therapeutic efficacy with reduced systemic side effects by rapamycin-loaded subcapsular microspheres.

Authors:  Lucas L Falke; Stefan H van Vuuren; Filis Kazazi-Hyseni; Farshad Ramazani; Tri Q Nguyen; Gert J Veldhuis; Erik M Maarseveen; Jurjen Zandstra; Johan Zuidema; Luisa F Duque; Rob Steendam; Eliane R Popa; Robbert Jan Kok; Roel Goldschmeding
Journal:  Biomaterials       Date:  2014-12-16       Impact factor: 12.479

Review 4.  Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier.

Authors:  Eric C Martens; Mareike Neumann; Mahesh S Desai
Journal:  Nat Rev Microbiol       Date:  2018-08       Impact factor: 60.633

5.  When Do You Start and When Do You Stop Screening for Colon Cancer in Inflammatory Bowel Disease?

Authors:  Millie D Long; Bruce E Sands
Journal:  Clin Gastroenterol Hepatol       Date:  2018-02-14       Impact factor: 11.382

Review 6.  Silk nanoparticles: from inert supports to bioactive natural carriers for drug delivery.

Authors:  Barbara Crivelli; Sara Perteghella; Elia Bari; Milena Sorrenti; Giuseppe Tripodo; Theodora Chlapanidas; Maria Luisa Torre
Journal:  Soft Matter       Date:  2018-01-24       Impact factor: 3.679

7.  Silk fibroin nanoparticles for cellular uptake and control release.

Authors:  Joydip Kundu; Yong-Il Chung; Young Ha Kim; Giyoong Tae; S C Kundu
Journal:  Int J Pharm       Date:  2010-01-08       Impact factor: 5.875

8.  TNFα gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitis.

Authors:  Bo Xiao; Qiubing Chen; Zhan Zhang; Lixin Wang; Yuejun Kang; Timothy Denning; Didier Merlin
Journal:  J Control Release       Date:  2018-08-11       Impact factor: 9.776

9.  Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation.

Authors:  Bo Xiao; Zhan Zhang; Emilie Viennois; Yuejun Kang; Mingzhen Zhang; Moon Kwon Han; Jiucun Chen; Didier Merlin
Journal:  Theranostics       Date:  2016-09-25       Impact factor: 11.556

10.  Antheraea pernyi silk fibroin-coated PEI/DNA complexes for targeted gene delivery in HEK 293 and HCT 116 cells.

Authors:  Yu Liu; Renchuan You; Guiyang Liu; Xiufang Li; Weihua Sheng; Jicheng Yang; Mingzhong Li
Journal:  Int J Mol Sci       Date:  2014-04-25       Impact factor: 5.923

View more
  5 in total

1.  Can naturally occurring nanoparticle-based targeted drug delivery effectively treat inflammatory bowel disease?

Authors:  Chunhua Yang; Didier Merlin
Journal:  Expert Opin Drug Deliv       Date:  2019-11-28       Impact factor: 6.648

2.  Multi-responsive nanotheranostics with enhanced tumor penetration and oxygen self-producing capacities for multimodal synergistic cancer therapy.

Authors:  Shuangquan Gou; Nanxi Chen; Xiaoai Wu; Menghang Zu; Shixiong Yi; Binwu Ying; Fangyin Dai; Bowen Ke; Bo Xiao
Journal:  Acta Pharm Sin B       Date:  2021-07-08       Impact factor: 11.413

3.  Nanoparticles Isolated From Porcine Bone Soup Ameliorated Dextran Sulfate Sodium-Induced Colitis and Regulated Gut Microbiota in Mice.

Authors:  Huiqin Wang; Jin Huang; Yanan Ding; Jianwu Zhou; Guanzhen Gao; Huan Han; Jingru Zhou; Lijing Ke; Pingfan Rao; Tianbao Chen; Longxin Zhang
Journal:  Front Nutr       Date:  2022-03-29

4.  Mucus-Penetrating Silk Fibroin-Based Nanotherapeutics for Efficient Treatment of Ulcerative Colitis.

Authors:  Dengchao Xie; Xin Zhou; Bo Xiao; Lian Duan; Zhenhua Zhu
Journal:  Biomolecules       Date:  2022-09-08

Review 5.  The interaction between nanoparticles and immune system: application in the treatment of inflammatory diseases.

Authors:  Jin Liu; Zeyang Liu; Yan Pang; Huifang Zhou
Journal:  J Nanobiotechnology       Date:  2022-03-12       Impact factor: 10.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.